{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT01522716",
      "OrgStudyIdInfo": {
        "OrgStudyId": "MSC-cGVH"
      },
      "Organization": {
        "OrgFullName": "Karolinska Institutet",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Mesenchymal Stromal Cells as Treatment of Chronic Graft-versus-host Disease",
      "OfficialTitle": "Mesenchymal Stromal Cells as Treatment of Chronic Graft-versus-host Disease"
    },
    "StatusModule": {
      "StatusVerifiedDate": "November 2020",
      "OverallStatus": "Terminated",
      "WhyStopped": "New requirements for study approval with the Swedish Medical Products Agency",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "August 2011"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "March 2016",
        "PrimaryCompletionDateType": "Actual"
      },
      "CompletionDateStruct": {
        "CompletionDate": "March 2017",
        "CompletionDateType": "Actual"
      },
      "StudyFirstSubmitDate": "January 24, 2012",
      "StudyFirstSubmitQCDate": "January 27, 2012",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "February 1, 2012",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "November 23, 2020",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "November 25, 2020",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Principal Investigator",
        "ResponsiblePartyInvestigatorFullName": "Lena von Bahr",
        "ResponsiblePartyInvestigatorTitle": "Leg läkare",
        "ResponsiblePartyInvestigatorAffiliation": "Karolinska Institutet"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Karolinska Institutet",
        "LeadSponsorClass": "OTHER"
      },
      "CollaboratorList": {
        "Collaborator": [
          {
            "CollaboratorName": "Region Stockholm",
            "CollaboratorClass": "OTHER_GOV"
          }
        ]
      }
    },
    "OversightModule": {
      "OversightHasDMC": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "The aim of the study is to evaluate the safety and efficacy of mesenchymal stromal cells as treatment for steroid-refractory chronic graft-versus-host disease."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Graft-Versus-Host Disease"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "N/A",
        "DesignInterventionModel": "Single Group Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "11",
        "EnrollmentType": "Actual"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Mesenchymal stromal cell treatment",
            "ArmGroupType": "Experimental",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: Mesenchymal stromal cells"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "Mesenchymal stromal cells",
            "InterventionDescription": "Allogenous mesenchymal stromal cells, to be injected intravenously at a dose of 1-2 million/kg at a frequency of once a month (frequency may be changed during the study if deemed appropriate by investigators) for 6-9 months.",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Mesenchymal stromal cell treatment"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Change in disease activity according to National Institute of Health criteria",
            "PrimaryOutcomeDescription": "Patients are evaluated according to NIH criteria at 3, 6 and (if applicable) 9 months after initialising MSC treatment, and the score compared to baseline score.",
            "PrimaryOutcomeTimeFrame": "Baseline to 9 months"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Change in disease activity as measured by histological examination",
            "SecondaryOutcomeTimeFrame": "Baseline to 9 months"
          },
          {
            "SecondaryOutcomeMeasure": "Change in self-assessed disease activity and quality of life",
            "SecondaryOutcomeTimeFrame": "Baseline to 9 months"
          },
          {
            "SecondaryOutcomeMeasure": "Safety (Adverse events, infections and relapse)",
            "SecondaryOutcomeDescription": "Frequency of complications, infections and relapse",
            "SecondaryOutcomeTimeFrame": "21 months"
          },
          {
            "SecondaryOutcomeMeasure": "Freedom from steroids at 1 year after MSC treatment",
            "SecondaryOutcomeDescription": "Proportion of patients free from corticosteroids at 1 year after finishing MSC treatment.",
            "SecondaryOutcomeTimeFrame": "1 year after finishing treatment"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nChronic graft-versus-host disease, grade moderate or severe despite at least 3 months treatment with calcineurin inhibitors and steroids OR\nChronic graft-versus-host disease, grade moderate or severe, where full treatment with calcineurin inhibitors and steroids is impossible due to intolerable side-effects\n\nExclusion Criteria:\n\nActive malignancy\nFulfilling criteria for previously initiated study for treatment of chronic graft-versus-host disease",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Hematology Center, Karolinska University Hospital Huddinge",
            "LocationCity": "Stockholm",
            "LocationCountry": "Sweden"
          }
        ]
      }
    },
    "ReferencesModule": {
      "ReferenceList": {
        "Reference": [
          {
            "ReferencePMID": "32573983",
            "ReferenceType": "derived",
            "ReferenceCitation": "Boberg E, von Bahr L, Afram G, Lindström C, Ljungman P, Heldring N, Petzelbauer P, Garming Legert K, Kadri N, Le Blanc K. Treatment of chronic GvHD with mesenchymal stromal cells induces durable responses: A phase II study. Stem Cells Transl Med. 2020 Oct;9(10):1190-1202. doi: 10.1002/sctm.20-0099. Epub 2020 Jun 23."
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000006086",
            "ConditionMeshTerm": "Graft vs Host Disease"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000007154",
            "ConditionAncestorTerm": "Immune System Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M8341",
            "ConditionBrowseLeafName": "Graft vs Host Disease",
            "ConditionBrowseLeafAsFound": "Graft Versus Host Disease",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M9352",
            "ConditionBrowseLeafName": "Immune System Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T2832",
            "ConditionBrowseLeafName": "Homologous Wasting Disease",
            "ConditionBrowseLeafAsFound": "Graft Versus Host Disease",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "T1303",
            "ConditionBrowseLeafName": "Chronic Graft Versus Host Disease",
            "ConditionBrowseLeafAsFound": "Chronic Graft Versus Host Disease",
            "ConditionBrowseLeafRelevance": "high"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC20",
            "ConditionBrowseBranchName": "Immune System Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "Rare",
            "ConditionBrowseBranchName": "Rare Diseases"
          }
        ]
      }
    }
  }
}